白念珠菌耐药机制新进展

中国真菌学杂志　 2013, Vol. 8 　Issue (5): 311-315.

白念珠菌耐药机制新进展

颜钰^1,2, 曹颖瑛^1,2, 姜远英^1,2

1. 福建中医药大学药学院中药学教研室, 福州 350000;
2. 第二军医大学药学院新药研究中心, 上海 200433

收稿日期:2013-03-01 出版日期:2013-10-28 发布日期:2013-10-28
通讯作者: 曹颖瑛,E-mail:caoyingying608@163.com E-mail:caoyingying608@163.com
作者简介:颜钰,女 (汉族),硕士研究生在读.E-mail:yanyu362429@126.com
基金资助:
国家自然科学基金(81271798),国家973项目(2013CB531602)

New progress on the drug resistance mechanisms of Candida albicans

CAO Ying-ying^1,2, CAO Ying-ying^1,2, JIANG Yuan-ying^1,2

1. Department of Pharmacy, Fujian Traditional Chinese Medicine University, Fuzhou 350000;
2. New Drug Reseach and Development Center, school of Pharmacology, Second Military Medical University, Shanghai 200433

Received:2013-03-01 Online:2013-10-28 Published:2013-10-28

摘要/Abstract

摘要： 近年来对于深部真菌感染的研究报道越来越多,其已日益成为一些重要疾病临床治疗过程中的常见并发症,其中,白念珠菌病的发病率仍居高不下。虽然目前有多种抗真菌药物应用于临床,但其耐药现象愈来愈严重,给临床治疗带来了极大的挑战。近来有关白念珠菌耐药机制的研究有了较新的进展。该文就新发现的白念珠菌的耐药机制,作一概述。

关键词: 白念珠菌, 耐药机制, 进展

Abstract: In recent years, more and more research about deep fungal infections has been reported, it has increasingly become the common complications during the clinical treatment of several important diseases, among which, the incidence of candidiasis remains unacceptably high. Although there are many kinds of antifungal drugs used in clinic, the drug resistance is becoming more and more serious, which has brought great challenge to the clinical treatment. Recent studies on the mechanism of drug resistance of Candida albicans showed new progress. In this article, the new mechanisms of drug resistance about C.albicans are reviewed briefly.

Key words: Candida albicans, drug resistance mechanisms, progress

中图分类号:

R379.4

颜钰, 曹颖瑛, 姜远英. 白念珠菌耐药机制新进展[J]. 中国真菌学杂志, 2013, 8(5): 311-315.

CAO Ying-ying, CAO Ying-ying, JIANG Yuan-ying. New progress on the drug resistance mechanisms of Candida albicans[J]. Chinese Journal of Mycology, 2013, 8(5): 311-315.

参考文献

[1] AkinsR A. An update on antifungal targets and mechanisms of resistance in Candida albicans[J]. Med Mycol, 2005,43(4): 285-318.
[2] Morschhauser J.The genetic basis of fluconazole resistance development in Candida albicans[J].Biochim Biophys Acta, 2002,1587(2-3):240-248.
[3] Guinea J, Sanchez-Somolinos M, Cuevas O, et al. Fluconazole resistance mechanisms in Candida krusei: the contribution of efflux-pumps[J].Med Mycol, 2006,44(6):575-578.
[4] Mansfield BE, Oltean HN, Oliver BG, et al. Azole drugs are imported by facilitated diffusion in Candida albicans and other pathogenic fungi[J]. PLoS Pathog, 2010,6(9): e1001126.
[5] Chau AS, Gurnani M, Hawkinson R, et al. Inactivation of sterol △^5,6-desaturase attenuates virulence in Candida albicans[J]. Antimicrob Agents Chemotherapy,2005,49 (9):3646-3651.
[6] Coste A,Turner V, Ischer F, et al.A mutationin Taclp,a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans[J].Genetics, 2006,172(4):2139-2156.
[7] Dunkel N, Blass J, Rogers PD, Morschhäuser J. Mutations in the multidrug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains[J]. Mol Microbiol, 2008, 69(4): 827-840.
[8] Dunkel N, Liu TT, Barker KS, et al. A Gain-of-Function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate[J]. Eukaryotic Cell, 2008, 7(7):1180-1190.
[9] Znaidi S, Barker KS, Weber S, et al. Identification of the Candida albicans Cap1p Regulon[J]. Eukaryotic Cell, 2009, 8(6):806-820.
[10] Schubert S, Barker KS, Znaidi S, et al. Regulation of efflux pump expression and drug resistance by the transcription factors Mrr1, Upc2, and Cap1 in Candida albicans[J]. Antimicrob Agents Chemother, 2011, 55(5):2212-2223.
[11] Coste AT, Ramsdale M, Ischer F, et al. Divergent functions of three Candida albicans zinc-cluster transcription factors (CTA4, ASG1 and CTF1) complementing pleiotropic drug resistance in Saccharomyces cerevisiae[J].Microbiology, 2008, 154(5):1491-1501.
[12] Plaine A, Walker L, Da Costa G, et al. Functional analysis of Candida albicans GPI-anchored proteins: roles in cell wall integrity and caspofungin sensitivity[J]. Fungal Genet Biol, 2008,45 (10):1404-1414.
[13] Lee KK, MacCallum DM, Jacobsen MD, et al. Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo[J]. Antimicrob Agents Chemother, 2012,56(1):208-217.
[14] Ene IV, Adya AK, Wehmeier S, et al. Host carbon sources modulate cell wall architecture, drug resistance and virulence in a fungal pathogen[J]. Cell Microbiol. 2012,14(9):1319-1335.
[15] Santos M, Larrinoa IF.Functional characterization of the Candida albicans CRZ1 gene encoding a calcineurin-regulated transcription factor[J].Current Genetics,2005,48 (2):88-100.
[16] Jia XM, Ma ZP, Jia Y, Gao PH, et al. RTA2, a novel gene involved in azole resistance in Candida albicans[J]. Biochem Biophys Res Commun.,2008, 373(4):631-636.
[17] Jia XM, Wang Y, Jia Y, et al. RTA2 is involved in calcineurin-mediated azole resistance and sphingoid long-chain base release in Candida albicans[J].Cell Mol Life Sci., 2009, 66(1):122-134.
[18] Jia Y, Tang RJ, Wang L, Zhang X, Wang Y, et al. Calcium-activated-calcineurin reduces the in vitro and in vivo sensitivity of fluconazole to Candida albicans via Rta2p[J]. PLoS ONE, 2012, 7(10): e48369.
[19] Cowen LE, Carpenter AE, Matangkasombut O, et al.Genetic architecture of Hsp90-dependent drug resistance[J]. Eukaryot Cell, 2006,5(12):2184 -2188.
[20] Cowen LE, Lindquist S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi[J]. Science 2005, 309(5744):2185-2189.
[21] Singh SD, Robbins N, Zaas AK, et al. Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog, 2009, 5(7): e1000532.
[22] Shapiro RS, Uppuluri P, Zaas AK, et al. Hsp90 Orchestrates Temperature-Dependent Candida albicans Morphogenesis via Ras1-PKA Signaling[J].Current Biology, 2009,19(8):621-629.
[23] Robbins N, Leach MD, Cowen LE. Lysine deacetylases Hda1 and Rpd3 regulate Hsp90 function thereby governing fungal drug resistance[J]. Cell Reports, 2012, 2(4): 878-888.
[24] Chandra J, Kuhn DM, Mukherjee PK, et al. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance[J]. J Bacteriol, 2001, 183(8):5385-5394.
[25] Mukherjee PK, Chandra J. Candida biofilm resistance.[J]. 2004, 7(4-5):301-309.
[26] Bink A, Vandenbosch D, Coenye T, et al. Superoxide dismutases are involved in Candida albicans biofilm persistence against miconazole[J]. Antimicrob Agents Chemother,2011, 55(9):4033-4037.
[27] Seneviratne CJ, Jin L, Samaranayake LP. Biofilm lifestyle of Candida: a mini review[J]. Oral Dis, 2008, 14 (7):582-590.
[28] Nett J, Lincoln L, Marchillo K, et al. Putative Role of β-1,3 Glucans in Candida albicans Biofilm Resistance[J]. Antimicrob Agents Chemother, 2007, 51(2):510-520.
[29] Nett JE, Crawford K, Marchillo K, et al. Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene[J]. Antimicrob Agents Chemother,2010,54(8):3505-3508.
[30] Bink A, Govaert G,Vandenbosch D, et al. Transcription factor Efg1 contributes to the tolerance of Candida albicans biofilms against antifungal agents in vitro and in vivo[J]. J Med Microbiol,2012, 61(6):813-819.